JP5298134B2 - 免疫抑制ポリペプチドおよび核酸 - Google Patents

免疫抑制ポリペプチドおよび核酸 Download PDF

Info

Publication number
JP5298134B2
JP5298134B2 JP2010532121A JP2010532121A JP5298134B2 JP 5298134 B2 JP5298134 B2 JP 5298134B2 JP 2010532121 A JP2010532121 A JP 2010532121A JP 2010532121 A JP2010532121 A JP 2010532121A JP 5298134 B2 JP5298134 B2 JP 5298134B2
Authority
JP
Japan
Prior art keywords
polypeptide
fusion protein
seq
amino acid
dimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010532121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502479A5 (OSRAM
JP2011502479A (ja
Inventor
エリック イー． カーラー
マダン エム． ペイドハンガット
スティーブン エイチ． バス
マーガレット ネイバーズ
ユハ プノネン
スティーブン ジェイ． チャピン
シュリダール ヴィシュワナータン
ブレント アール． ラーセン
Original Assignee
パーシード セラピューティクス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーシード セラピューティクス リミテッド ライアビリティ カンパニー filed Critical パーシード セラピューティクス リミテッド ライアビリティ カンパニー
Publication of JP2011502479A publication Critical patent/JP2011502479A/ja
Publication of JP2011502479A5 publication Critical patent/JP2011502479A5/ja
Application granted granted Critical
Publication of JP5298134B2 publication Critical patent/JP5298134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2010532121A 2007-11-01 2008-10-15 免疫抑制ポリペプチドおよび核酸 Active JP5298134B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98463107P 2007-11-01 2007-11-01
US60/984,631 2007-11-01
US5121508P 2008-05-07 2008-05-07
US61/051,215 2008-05-07
PCT/US2008/079981 WO2009058564A2 (en) 2007-11-01 2008-10-15 Immunosuppressive polypeptides and nucleic acids

Publications (3)

Publication Number Publication Date
JP2011502479A JP2011502479A (ja) 2011-01-27
JP2011502479A5 JP2011502479A5 (OSRAM) 2013-01-31
JP5298134B2 true JP5298134B2 (ja) 2013-09-25

Family

ID=40124836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532121A Active JP5298134B2 (ja) 2007-11-01 2008-10-15 免疫抑制ポリペプチドおよび核酸

Country Status (20)

Country Link
US (8) US7794718B2 (OSRAM)
EP (4) EP2385065A1 (OSRAM)
JP (1) JP5298134B2 (OSRAM)
KR (1) KR101383476B1 (OSRAM)
CN (2) CN101998965B (OSRAM)
AU (1) AU2008319053B2 (OSRAM)
CA (1) CA2703263C (OSRAM)
CY (1) CY1113713T1 (OSRAM)
DK (1) DK2222697T3 (OSRAM)
ES (2) ES2399088T3 (OSRAM)
HR (1) HRP20130194T1 (OSRAM)
IL (1) IL205036A (OSRAM)
MX (1) MX2010004883A (OSRAM)
PH (1) PH12013501101A1 (OSRAM)
PL (2) PL2222697T3 (OSRAM)
PT (2) PT2222697E (OSRAM)
RU (1) RU2506275C2 (OSRAM)
TW (1) TWI448473B (OSRAM)
WO (1) WO2009058564A2 (OSRAM)
ZA (1) ZA201002872B (OSRAM)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
KR101580938B1 (ko) 2007-06-01 2015-12-30 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
ES2632504T3 (es) * 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
NO2344540T3 (OSRAM) 2008-10-02 2018-04-28
WO2011017159A2 (en) * 2009-07-28 2011-02-10 Ligacept, Llc Broad spectrum erbb ligand binding molecules and methods for preparing and using them
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
KR101193940B1 (ko) * 2009-12-14 2012-10-24 고려대학교 산학협력단 레서스 원숭이 ｃｔｌａ-4 융합 이뮤노글로불린
LT3053932T (lt) * 2010-02-19 2020-11-10 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
WO2012159075A1 (en) * 2011-05-19 2012-11-22 Seattle Biomedical Research Institute Bioprobe compositions and their methods of use
CN102391377B (zh) * 2011-11-01 2013-11-06 孙嘉琳 一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
CN102382193B (zh) * 2011-11-01 2013-08-14 孙嘉琳 诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
CN102516392B (zh) * 2011-11-25 2014-05-28 孙嘉琳 一种癌靶向超抗原融合蛋白及制备方法及用途
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
JP6228971B2 (ja) * 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
WO2014100073A2 (en) * 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN104277112B (zh) * 2013-07-04 2018-01-26 嘉和生物药业有限公司 长效降血糖融合蛋白
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11340235B2 (en) 2014-02-28 2022-05-24 Ga Generic Assays Gmbh GP2 isoforms and their use in autoantibody capture
CN103923934B (zh) * 2014-03-22 2016-11-02 复旦大学 一种具有免疫负调控作用的基因工程蛋白及其制备方法与应用
KR102161927B1 (ko) 2014-04-25 2020-10-06 블루버드 바이오, 인코포레이티드. 양자 세포 치료제를 제조하는 개선된 방법
SG10201900455YA (en) 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
WO2016094304A2 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
AU2016256217B2 (en) * 2015-04-28 2020-04-16 Swedish Orphan Biovitrum Ab (Publ) Compositions comprising anakinra
CN108368165A (zh) * 2015-06-24 2018-08-03 德克萨斯大学系统董事会 用于治疗颅内出血相关症状的方法和组合物
ES2846024T7 (es) 2015-07-24 2023-06-22 Gliknik Inc Proteínas de fusión de fragmentos de proteína humana para crear composiciones de Fc de inmunoglobulina multimerizada de forma ordenada con unión al complemento aumentada
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
KR101969513B1 (ko) 2015-08-21 2019-04-16 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
CA2996652A1 (en) * 2015-09-01 2017-03-09 Immunwork Inc. Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
WO2017044424A1 (en) * 2015-09-08 2017-03-16 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
KR20180069903A (ko) * 2015-11-02 2018-06-25 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins and CD80 variants and their uses
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
WO2017214834A1 (zh) * 2016-06-14 2017-12-21 石庆学 特异促进 ctla-4 基因高表达的慢病毒表达载体及其应用
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041121A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
CN110022906A (zh) 2016-11-04 2019-07-16 蓝鸟生物公司 抗bcma car t细胞组合物
JP2020503855A (ja) 2016-12-09 2020-02-06 グリックニック インコーポレイテッド 多量体化ストラドマーｇｌ−２０４５の製造最適化
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
MX2019012849A (es) * 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
CA3077509A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
IL320945A (en) 2017-10-18 2025-07-01 Alpine Immune Sciences Inc Immunomodulatory proteins, ligands for ICOs, and compositions and methods related thereto
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
JP7368007B2 (ja) * 2018-07-24 2023-10-24 グッド ティー セルズ、 インコーポレイテッド 免疫関連疾患の予防または治療用組成物
US20210340214A1 (en) * 2018-08-29 2021-11-04 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
JP7652422B2 (ja) * 2018-11-02 2025-03-27 ベイジン ブイディージェイバイオ カンパニー， リミテッド 修飾されたｃｔｌａ４およびその使用方法
EP3948281A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Spr-based binding assay for the functional analysis of multivalent molecules
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
WO2020210596A1 (en) * 2019-04-10 2020-10-15 University Of Kentucky Research Foundation Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use
JP7405361B2 (ja) * 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
RU2760578C2 (ru) * 2019-12-25 2021-11-29 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Слитый белок, содержащий модифицированный безметиониновый белок GroEL и димер полипептида полифемузина I
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
CU24723B1 (es) * 2021-01-29 2024-12-09 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica que comprende el ghrp-6
AU2022227552A1 (en) * 2021-02-23 2023-10-05 University Of Washington Compositions and methods for cardiomyocyte transplantation
JP2024510291A (ja) * 2021-03-16 2024-03-06 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫疾患を治療するための二機能性分子
EP4323388B1 (en) 2021-04-16 2025-01-29 Athebio AG N-terminal capping modules of ankyrin repeat domains
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
CN115719614A (zh) * 2021-08-27 2023-02-28 予果生物科技（北京）有限公司 一种基于隐藏亚组的生信降噪分析方法及系统
AU2022399232A1 (en) * 2021-11-26 2024-07-04 Imunexus Therapeutics Limited Binding domain molecules on cell surfaces
EP4448584A4 (en) * 2021-12-17 2025-12-03 Kashiv Biosciences Llc IMPROVED ASSAY METHOD FOR DETERMINING THE POTENCY OF A RECOMBINATING PROTEIN
US20250263690A1 (en) * 2022-06-15 2025-08-21 Duke University Protein library display systems and methods thereof
EP4573106A2 (en) 2022-08-16 2025-06-25 Athebio AG Variants of ankyrin repeat domains
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US511A (en) * 1837-12-15 Improved mode of coloring and finishing leather
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
CA1200773A (en) 1980-02-29 1986-02-18 William J. Rutter Expression linkers
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS60188070A (ja) 1984-03-09 1985-09-25 Kunio Yamane シグナルペプチドをコードするｄｎａ
GB8412517D0 (en) 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
WO1987000201A1 (en) 1985-07-05 1987-01-15 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
KR890003620Y1 (ko) 1985-07-25 1989-05-27 삼성전자주식회사 전자레인지의 파워릴레이 구동회로
CA1293460C (en) 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5084384A (en) 1987-04-23 1992-01-28 Monsanto Company Secretion of insulin-like growth factor-I
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
US5017478A (en) 1987-07-16 1991-05-21 Berlex Laboratories, Inc. Transfected cells containing plasmids having genes oriented in opposing directions and methods of using
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
EP1762623A1 (en) 1988-01-22 2007-03-14 ZymoGenetics, Inc. Methods for producing biologically active peptide dimers
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5284768A (en) 1988-08-24 1994-02-08 Sanofi Signal peptide, DNA sequences coding for the latter, expression vectors carrying one of these sequences, gram-negative bacteria transformed by these vectors, and process for the periplasmic production of a polypeptide
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
DE3901681A1 (de) 1989-01-21 1990-07-26 Behringwerke Ag Signalpeptid fuer die sekretion von peptiden in escherichia coli, verfahren zu seiner gewinnung und seine verwendung
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
CA2067821A1 (en) 1989-10-24 1991-04-25 Cetus Oncology Corporation Infective drug delivery system using recombinant retroviral vectors
CA2044593C (en) 1989-11-03 2004-04-20 Kenneth L. Brigham Method of in vivo delivery of functioning foreign genes
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
CA2106474C (en) 1991-03-19 2004-02-10 R. Martin Emanuele Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ES2123001T5 (es) 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5506098A (en) 1991-09-04 1996-04-09 Daikin Industries, Ltd. In situ hybridization method
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
ATE272708T1 (de) 1992-04-07 2004-08-15 Univ Michigan Immunregulation über die cd28-route
US5792751A (en) 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
EP0621337A1 (en) 1993-01-25 1994-10-26 American Cyanamid Company Codon optimized DNA sequence for insect toxin AaIT
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6482919B2 (en) 1993-02-01 2002-11-19 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69435075T2 (de) 1993-03-17 2009-02-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
DE69431295T2 (de) 1993-04-21 2003-05-15 Institut Pasteur, Paris Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
CA2158937C (en) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Recombinant alphavirus vectors
US6107095A (en) 1993-11-26 2000-08-22 Mazurkiewicz; Marian Method for introducing substances into living cells and tissues
US5580766A (en) 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
ES2192573T3 (es) 1994-01-21 2003-10-16 Powderject Vaccines Inc Instrumento de deposito de genes mediante arrastre gaseoso.
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5601820A (en) 1994-07-07 1997-02-11 Children's Hospital Of Philadelphia Compositions and methods of making and using human full length TRK-B
US5855579A (en) * 1994-07-15 1999-01-05 Smith & Nephew, Inc. Cannulated modular intramedullary nail
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5750340A (en) 1995-04-07 1998-05-12 University Of New Mexico In situ hybridization solution and process
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5525510A (en) 1995-06-02 1996-06-11 Agracetus, Inc. Coanda effect gene delivery instrument
DE69634297T2 (de) 1995-06-05 2006-01-05 University Of Washington, Seattle Verfahren zur verlängerung der expression eines interessierenden gens unter verwendung von löslichen ctla4 molekülen
US5993800A (en) 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997004748A2 (en) 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
US5966560A (en) * 1995-08-29 1999-10-12 Minolta Co., Ltd. Image forming apparatus with enhanced pretransfer erasing
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
JP2000500121A (ja) 1995-09-27 2000-01-11 エモリー・ユニバーシティー 免疫系による生きた被移植細胞の破壊を阻止する方法
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2248140C (en) * 1996-03-04 2005-02-01 Ronald P. Mischak Assay and reagents for quantifying hbnp
PT892643E (pt) 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
WO1998002535A1 (en) 1996-07-11 1998-01-22 Takara Shuzo Co., Ltd. Method for effecting site-directed mutagenesis
WO1998006863A1 (en) 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6107477A (en) 1996-09-26 2000-08-22 Aurora Biosciences Corporation Non-optimal Kozaks sequences
KR100620481B1 (ko) 1996-10-23 2006-09-06 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
AU745409B2 (en) 1997-01-29 2002-03-21 Cornell Research Foundation Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
CN1198665C (zh) 1997-04-03 2005-04-27 依莱克脱罗弗克脱联合股份有限公司 将药物和核酸导入骨骼肌的方法
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6225082B1 (en) 1997-05-09 2001-05-01 Research Corporation Technologies, Inc. Myelin basic protein MRNA transport and translation enhancer sequences
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
DE69820450T2 (de) 1997-06-09 2004-05-27 Genvec, Inc. Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
DE19729058A1 (de) 1997-07-08 1999-01-14 Sika Ag Verbundelement und Verfahren zu seiner Herstellung
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20010007860A1 (en) 1997-07-14 2001-07-12 Christopher W. Olsen Method of dna vaccination
WO1999008689A1 (en) 1997-08-21 1999-02-25 Powderject Vaccines, Inc. Mucosal immunization using particle-mediated delivery techniques
CA2304173A1 (en) 1997-09-23 1999-04-01 Genvec, Inc. Plasmids for construction of eukaryotic viral vectors
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1053343A2 (en) 1998-02-11 2000-11-22 Maxygen, Inc. Targeting of genetic vaccine vectors
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
AU3107699A (en) 1998-03-19 1999-10-11 Heska Corporation Novel forms of t cell costimulatory proteins, nucleic acid molecules, and uses thereof
US6121236A (en) 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
PL343630A1 (en) 1998-04-22 2001-08-27 Genvec Inc Efficient purification of adenovirus
AU3739999A (en) 1998-05-06 1999-11-23 Pharmacia & Upjohn Company Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6225113B1 (en) 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
SG143018A1 (en) 1998-12-23 2008-06-27 Pfizer Human monoclonal antibodies to ctla-4
WO2000039318A1 (en) 1998-12-31 2000-07-06 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
AU2001249380A1 (en) 2000-03-22 2001-11-07 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
CA2407050A1 (en) 2000-04-25 2001-11-01 Chiron Corporation Alphavirus-based vectors for persistent infection
US20020058039A1 (en) 2000-04-27 2002-05-16 Coyne Michael J. Method of measuring the duration of adequate immune memory in companion animals
UA87432C2 (uk) * 2000-05-26 2009-07-27 Бристол-Майерс Сквибб Компани Розчинний мутантний ctla4 та його застосування
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AU2001272978A1 (en) * 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU2001268716A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
US20050154189A1 (en) * 2000-06-23 2005-07-14 Maxygen Inc Novel co-stimulatory molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PL212205B1 (pl) * 2000-07-03 2012-08-31 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
AU2001271839A1 (en) * 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
FR2843396B1 (fr) * 2002-08-07 2005-04-15 Bio Rad Pasteur Anticorps specifiques pour le diagnostic de l'insuffisance cardiaque
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
SI1576182T2 (sl) 2002-12-23 2020-07-31 Bristol-Myers Squibb Company Izboljšava kvalitete izdelka v procesih pridelave beljakovin v celični kulturi sesalcev
CA2762015A1 (en) 2003-08-04 2005-02-24 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble ctla4 molecule
US7731965B2 (en) * 2005-02-17 2010-06-08 Abbott Lab Human ring specific BNP antibodies
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
EA013122B1 (ru) 2005-04-06 2010-02-26 Бристол-Маерс Сквибб Компани Способы лечения иммунных нарушений, связанных с пересадкой трансплантата, растворимым мутантным ctla4
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
RU2506275C2 (ru) * 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Also Published As

Publication number Publication date
CN101998965A (zh) 2011-03-30
EP2385065A1 (en) 2011-11-09
EP2612867A1 (en) 2013-07-10
US8491899B2 (en) 2013-07-23
TWI448473B (zh) 2014-08-11
US20100260759A1 (en) 2010-10-14
US8071095B2 (en) 2011-12-06
DK2222697T3 (da) 2013-03-11
US20110182898A1 (en) 2011-07-28
WO2009058564A3 (en) 2010-01-14
US8268587B2 (en) 2012-09-18
CY1113713T1 (el) 2016-06-22
US20110159542A1 (en) 2011-06-30
EP2612868B1 (en) 2018-08-15
ES2688721T3 (es) 2018-11-06
PH12013501101B1 (en) 2015-12-07
US20110129875A1 (en) 2011-06-02
US8318176B2 (en) 2012-11-27
WO2009058564A2 (en) 2009-05-07
US20110130546A1 (en) 2011-06-02
US20090258031A1 (en) 2009-10-15
EP2222697A2 (en) 2010-09-01
KR20100105551A (ko) 2010-09-29
EP2222697B1 (en) 2012-12-05
PL2222697T3 (pl) 2013-05-31
US8283447B2 (en) 2012-10-09
CN103172750A (zh) 2013-06-26
ES2399088T3 (es) 2013-03-25
IL205036A0 (en) 2010-11-30
EP2612868A1 (en) 2013-07-10
HRP20130194T1 (hr) 2013-04-30
PT2612868T (pt) 2018-10-24
JP2011502479A (ja) 2011-01-27
AU2008319053B2 (en) 2012-04-26
US20110166324A1 (en) 2011-07-07
CN101998965B (zh) 2014-03-12
CA2703263A1 (en) 2009-05-07
MX2010004883A (es) 2010-11-10
US8496935B2 (en) 2013-07-30
US20110177071A1 (en) 2011-07-21
KR101383476B1 (ko) 2014-04-11
CN103172750B (zh) 2014-12-10
TW200936607A (en) 2009-09-01
ZA201002872B (en) 2011-02-23
CA2703263C (en) 2014-03-18
RU2010122053A (ru) 2011-12-10
PL2612868T3 (pl) 2018-12-31
US7794718B2 (en) 2010-09-14
AU2008319053A1 (en) 2009-05-07
RU2506275C2 (ru) 2014-02-10
PT2222697E (pt) 2013-02-15
IL205036A (en) 2016-02-29
US8445230B2 (en) 2013-05-21
PH12013501101A1 (en) 2015-12-07

Similar Documents

Publication Publication Date Title
JP5298134B2 (ja) 免疫抑制ポリペプチドおよび核酸
KR20180012260A (ko) 조율가능한 친화성을 갖는 면역조절 단백질
CN101198347A (zh) 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法
AU2014250683B2 (en) Immunosuppressive polypeptides and nucleic acids
CA2805976C (en) Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) Immunosuppressive polypeptides and nucleic acids

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121219

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130617

R150 Certificate of patent or registration of utility model

Ref document number: 5298134

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250